Evidence suggests the existence of a linkage between inflammation, prostate cancer, and the chronic inflammation of the prostate gland, which may be a common symptomatology conducible to MetS patients, also associated with high levels of cytokines, interleukins, and growth factors, such as IL-6, MSR1, TNFα, and IL-8 [91], which induce prostate cell differentiation and storage in mutations and epigenetic point modifications [88]. This evidence concerns the gene TNF and prostate carcinoma.